These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12524581)

  • 21. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
    Alaghband-Rad J; Hakimshooshtary M
    Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial.
    Belotto-Silva C; Diniz JB; Malavazzi DM; Valério C; Fossaluza V; Borcato S; Seixas AA; Morelli D; Miguel EC; Shavitt RG
    J Anxiety Disord; 2012 Jan; 26(1):25-31. PubMed ID: 21907540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
    Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
    J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obsessive-compulsive disorder presenting with gender incongruence obsessions.
    Uvais NA; Sreeraj VS
    Asian J Psychiatr; 2017 Dec; 30():77-78. PubMed ID: 28837942
    [No Abstract]   [Full Text] [Related]  

  • 28. Obsessive-compulsive disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Apr; 27(2):116-30. PubMed ID: 24576790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
    Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
    Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline.
    Patzold T; Brüne M
    Neuropsychiatry Neuropsychol Behav Neurol; 2002 Sep; 15(3):216-9. PubMed ID: 12218715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recognition and treatment of obsessive-compulsive disorder.
    Goodman WK; Lydiard RB
    J Clin Psychiatry; 2007 Dec; 68(12):e30. PubMed ID: 18162010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
    Zitterl W; Meszaros K; Hornik K; Twaroch T; Dossenbach M; Zitterl-Eglseer K; Zapotoczky HG
    Wien Klin Wochenschr; 1999 Jun; 111(11):439-42. PubMed ID: 10420495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder.
    Leonard HL; Topol D; Bukstein O; Hindmarsh D; Allen AJ; Swedo SE
    J Am Acad Child Adolesc Psychiatry; 1994; 33(6):792-4. PubMed ID: 8083135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial.
    Hoexter MQ; de Souza Duran FL; D'Alcante CC; Dougherty DD; Shavitt RG; Lopes AC; Diniz JB; Deckersbach T; Batistuzzo MC; Bressan RA; Miguel EC; Busatto GF
    Neuropsychopharmacology; 2012 Feb; 37(3):734-45. PubMed ID: 22030709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Kim M; Kwak S; Yoon YB; Kwak YB; Kim T; Cho KIK; Lee TY; Kwon JS
    Neuropsychopharmacology; 2019 Nov; 44(12):2073-2081. PubMed ID: 31189178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
    Carrasco JL; Hollander E; Schneier FR; Liebowitz MR
    J Clin Psychiatry; 1992 Nov; 53(11):387-91. PubMed ID: 1459968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postpartum onset obsessive-compulsive disorder: diagnosis and management.
    Brandes M; Soares CN; Cohen LS
    Arch Womens Ment Health; 2004 Apr; 7(2):99-110. PubMed ID: 15083345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period.
    Brakoulias V; Viswasam K; Dwyer A; Raine KH; Starcevic V
    Expert Opin Pharmacother; 2020 Feb; 21(2):163-165. PubMed ID: 31893946
    [No Abstract]   [Full Text] [Related]  

  • 40. A multidimensional model of obsessive-compulsive disorder.
    Mataix-Cols D; Rosario-Campos MC; Leckman JF
    Am J Psychiatry; 2005 Feb; 162(2):228-38. PubMed ID: 15677583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.